ES2371515T3 - Agonistas del receptor grp119 acoplado a proteína g. piridona. - Google Patents

Agonistas del receptor grp119 acoplado a proteína g. piridona. Download PDF

Info

Publication number
ES2371515T3
ES2371515T3 ES08781867T ES08781867T ES2371515T3 ES 2371515 T3 ES2371515 T3 ES 2371515T3 ES 08781867 T ES08781867 T ES 08781867T ES 08781867 T ES08781867 T ES 08781867T ES 2371515 T3 ES2371515 T3 ES 2371515T3
Authority
ES
Spain
Prior art keywords
heterocyclyl
cycloalkyl
aryl
nr14r14
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08781867T
Other languages
English (en)
Inventor
Dean A. Wacker
Karen A. Rossi
Ying Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ES2371515T3 publication Critical patent/ES2371515T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)

Abstract

Un compuesto seleccionado entre los compuestos de Fórmula I y Fórmula IA: y enantiómeros, diastereómeros, solvatos y sales farmacéuticamente aceptables de los mismos que tienen un anillo A y un anillo B, en las que: el anillo A está opcionalmente sustituido con uno o más de R mostrados como R20 y R21; G es CH o N; Q es C o N; X es CH o N, con la condición de que Q y X no sean ambos N; Y es CH2, N(R3), C(=O), O, OCR9R9, S, S(=O) o S(O)2; n1 es 0-2; n2 es 0-2; n3 es 1-2; R1 es un arilo monocíclico de 6 miembros, un heteroarilo monocíclico de 5 miembros o un heteroarilo monocíclico de 6 miembros, pudiendo estar cada uno de los mismos opcionalmente sustituido con uno o más miembros seleccionados entre R1a, R1b, R1c, R1d y R1e; cada uno de R1a, R1b, R1c, R1d y R1e se selecciona independientemente entre el grupo que consiste en hidrógeno, alquilo, alquenilo, alquinilo, cicloalquilo, arilo, heterociclilo, halo,- NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR10, -OCF3, -OR11, -OH, -SH, -SR11r S(O)3H, -P(O)3H2, -C(=O)NR9R9, -NR12R12, -S(O)2NR9R9, -NR9S(O)2CF3, - C(=O)NR9S(O)2R9, -S(O)2NR9C(=O)OR9, -S(O)2NR9C(=O)NR9R9, -C(=O)NR9S(O)2CF3, -C(=O)R11, -NR9C(=O)H,- NR9C(=O)R10, -OC(=O)R10, -OC(=O)NR9R9, -C(=NR14)NR9R9, -NHC(=NR14)NR14R14, -S(=O)R11, -S(O)2R11, - NR9C(=O)OR8 y -NR9S(O2)R8, en los que: (a) cada uno de los alquenilo, alquinilo, cicloalquilo, arilo y heterociclilo puede estar opcionalmente sustituido con uno o más de R6; y (b) el alquilo puede estar opcionalmente sustituido con uno o más de R7; R2 es cicloalquilo, arilo, heteroarilo, heterociclilo, -S(O)2R5, -C(=O)NR3R5, -C(=O)R5 o -C(=O)OR5, en el que cada uno de los cicloalquilo, arilo, heteroarilo y heterociclilo puede estar opcionalmente sustituido con uno o más de R6; R3 es hidrógeno, alquilo, alcoxi, cicloalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo o heterociclilalquilo; R5 es alquilo, alquenilo, arilo, cicloalquilo, heteroarilo o heterociclilo, pudiendo estar cada uno de los mismos opcionalmente sustituido con uno o más de R6; R6, en cada caso, se selecciona independientemente entre alquilo, haloalquilo, arilo, alquenilo, alquinilo, cicloalquilo, cicloalquilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR10, -OCF3, -OR10, -OH, -SH, -SR10, -S(O)3H, -P(O)3H2, -C(=O)NR9R9, -NR9R9, -S(O)2NR9R9, - NR9S(O)2CF3, -C(=O)NR9S(O)2R9, -S(O)2NR9C(=O)OR9, -S(O)2NR9C(=O)NR9R9, -C(=O)NR9S(O)2CF3, - C(=O)R10, -NR9C(=O)H, -NR9C(=O)R10, -OC(=O)R10, -C(=NR14)NR9R9, -NHC(=NR14)NR14R14, -S(=O)R10, - S(O)2R10, =O, -NR9C(=O)OR8 y -NR9S(O2)R8, en el que cada uno de los alquilo, alquenilo, alquinilo, arilo, cicloalquilo, cicloalquilalquilo, heteroarilo, heteroarilalquilo, heterociclilo y heterociclilalquilo puede estar opcionalmente sustituido con 0-5 R9a; R7, en cada caso, se selecciona independientemente entre el grupo que consiste en alquilo, haloalquilo, arilo, alquenilo, alquinilo, cicloalquilo, cicloalquilalquilo, heterociclilo, halo, - NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR10, - OCF3, -OR10, -OH, -SH, -SR10, -S(O)3H, -P(O)3H2, -C(=O)NR9R9, -NR9R9, -S(O)2NR9R9, -NR9S(O)2CF3, - C(=O)NR9S(O)2R9, -S(O)2NR9C(=O)OR9, -S(O)2NR9C(=O)NR9R9, -C(=O)NR9S(O)2CF3, -C(=O)R10,-NR9C(=O)H, - NR9C(=O)R10, -OC(=O)R10, -C(=NR14)NR9R9,- NHC(=NR14)NR14R14, -S(=O)R10, -S(O)2R10, =O, -NR9C(=O)OR8 y -NR9S(O2)R8, en el que cada uno de los alquilo, alquinilo, alquinilo, arilo, cicloalquilo, cicloalquilalquilo y heterociclilo puede estar opcionalmente sustituido con 0-5 R9a; R8, en cada caso, se selecciona independientemente entre el grupo que consiste en alquilo, arilo, cicloalquilo, heteroarilo y heterociclilo, pudiendo estar cada uno de los mismos opcionalmente sustituido con uno o más de R8a; R8a, en cada caso, se selecciona independientemente entre alquilo, haloalquilo, arilo, alquenilo, alquinilo, cicloalquilo, cicloalquilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR14, -OCF3, -OR14, -OH, -SH, -SR14, -S(O)3H, -P(O)3H2, -C(=O)NR14R14, -NR14R14, - S(O)2NR14R14, -NR14S(O)2CF3, -C(=O)NR14S(O)2R14, -S(O)2NR14C(=O)OR14, -S(O)2NR14C(=O)NR14R14, - C(=O)NR14S(O)2CF3, -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14, -OC(=O)R14, -C(=NR14)NR14R14, -NHC(=NR14) NR14R14, -S(=O)R14, -S(O)2R14, =O, -NR14C(=O)OR14 y -NR14S(O2)R14; R9, en cada caso, se selecciona independientemente entre hidrógeno, alquilo, alcoxi, cicloalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo y heterociclilalquilo, en el que cada uno de los alquilo, cicloalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo y heterociclilalquilo puede estar opcionalmente sustituido con 0-5 R9a; R9a, en cada caso, se selecciona independientemente entre alquilo, haloalquilo, arilo, alquenilo, alquinilo, cicloalquilo, cicloalquilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR14, -OCF3, -OR14, -OH, -SH, -SR14, -S(O)3H, -P(O)3H2, -C(=O)NR14R14, -NR14R14, - S(O)2NR14R14, -NR14S(O)2CF3, -C(=O)NR14S(O)2R10, -S(O)2NR14C(=O)OR10, -S(O)2NR14C(=O)NR14R14, - C(=O)NR14S(O)2CF3, -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14, -OC(=O)R14, -C(=NR14)NR14R14, -NHC(=NR14) NR14R14, -S(=O)R14, -S(O)2R14, -NR14C(=O)OR8, -NR14S(O2)R8, =O y arilalquilo; R10, en cada caso, se selecciona independientemente entre alquilo, alquenilo, alquinilo, cicloalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo y heterociclilalquilo, en el que cada uno de los cicloalquilo, arilo, arilalquilo, heteroarilo, heteroarilalquilo, heterociclilo y heterociclilalquilo puede estar opcionalmente sustituido con 0-3 R10a; R10a, en cada caso, se selecciona independientemente entre alquilo, haloalquilo, arilo, alquenilo, alquinilo, cicloalquilo, cicloalquilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR14, -OCF3, -OR14, -OH, -SH, -SR14, -S(O)3H, -P(O)3H2, -C(=O)NR14R14, -NR14R14, S(O)2NR14R14, -NR14S(O)2CF3, -C(=O)NR14S(O)2R9, -S(O)2NR14C(=O)OR9, -S(O)2NR14C(=O)NR14R14, - C(=O)NR14S(O)2CF3, -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14, -OC(=O)R14, -C(=NR14)NR14R14, - NHC(=NR14)NR14R14, -S(=O)R14, -S(O)2R14, -NR14C(=O)OR8, -NR14S(O2)R8 y arilalquilo; R11, en cada caso, se selecciona independientemente entre alquilo, alquenilo, alquinilo, cicloalquilo, arilo, arilalquilo, heterociclilo y heterociclilalquilo, en el que cada uno de los cicloalquilo, arilo, arilalquilo, heterociclilo y heterociclilalquilo puede estar opcionalmente sustituido con 0-3 R11a; R11a, en cada caso, se selecciona independientemente entre alquilo, haloalquilo, arilo, alquenilo, alquinilo, cicloalquilo, cicloalquilalquilo, heteroarilo, heteroarilalquilo, heterociclilo, heterociclilalquilo, halo, -NH2, -CN, -NO2, -C(=O)OH, -C(=O)OR14, -OCF3, -OR14, -OH, -SH, -SR14, -S(O)3H, -P(O)3H2, -C(=O)NR14R14, -NR14R14, - S(O)2NR14R14, -NR14S(O)2CF3, -C(=O)NR14S(O)2R9, -S(O)2NR14C(=O)OR9, -S(O)2NR14C(=O)NR14R14, - C(=O)NR14S(O)2CF3, -C(=O)R14, -NR14C(=O)H, -NR14C(=O)R14, -OC(=O)R14, -C(=NR14)NR14R14, -NHC(=NR14) NR14R14, -S(=O)R14, -S(O)2R14, -NR14C(=O)OR8, -NR14S(O2)R8 y arilalquilo; R12, en cada caso, se selecciona independientemente entre hidrógeno, alquilo, alquenilo, alquinilo, cicloalquilo, arilo, arilalquilo, heterociclilo y heterociclilalquilo, en el que cada uno de los cicloalquilo, arilo, arilalquilo, heterociclilo y heterociclilalquilo puede estar opcionalmente sustituido con 0-3 R10a; R14, en cada caso, se selecciona independientemente entre hidrógeno, alquilo, cicloalquilo y arilo; y cada uno de R20 y R21 se selecciona independientemente entre el grupo que consiste en hidrógeno, alquilo, haloalquilo, cicloalquilo, halo, -CN, -C(=O)OH, -C(=O)OR10, -OCF3, -OR10, -OH, -C(=O)NR9R9, -C(=O)R10 y - OC(=O)R10.
ES08781867T 2007-07-17 2008-07-16 Agonistas del receptor grp119 acoplado a proteína g. piridona. Active ES2371515T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95016207P 2007-07-17 2007-07-17
US950162P 2007-07-17

Publications (1)

Publication Number Publication Date
ES2371515T3 true ES2371515T3 (es) 2012-01-04

Family

ID=39864683

Family Applications (2)

Application Number Title Priority Date Filing Date
ES08781868T Active ES2378914T3 (es) 2007-07-17 2008-07-16 Procedimientos para modular receptor acoplado a la proteína G GPR119 y compuestos seleccionados
ES08781867T Active ES2371515T3 (es) 2007-07-17 2008-07-16 Agonistas del receptor grp119 acoplado a proteína g. piridona.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES08781868T Active ES2378914T3 (es) 2007-07-17 2008-07-16 Procedimientos para modular receptor acoplado a la proteína G GPR119 y compuestos seleccionados

Country Status (26)

Country Link
US (6) US8003796B2 (es)
EP (2) EP2170864B1 (es)
JP (3) JP5318867B2 (es)
KR (2) KR20100051814A (es)
CN (3) CN103550218A (es)
AR (2) AR067568A1 (es)
AT (2) ATE524460T1 (es)
AU (2) AU2008276057B2 (es)
BR (2) BRPI0815097A2 (es)
CA (2) CA2693444A1 (es)
CL (2) CL2008002110A1 (es)
CO (1) CO6160315A2 (es)
CY (2) CY1112151T1 (es)
DK (2) DK2170864T3 (es)
EA (2) EA018709B1 (es)
ES (2) ES2378914T3 (es)
HR (2) HRP20120221T1 (es)
IL (1) IL228120A0 (es)
NZ (2) NZ582664A (es)
PE (2) PE20090449A1 (es)
PL (2) PL2170864T3 (es)
PT (2) PT2170864E (es)
SI (2) SI2173737T1 (es)
TW (2) TW200904440A (es)
WO (2) WO2009012277A1 (es)
ZA (2) ZA201000151B (es)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPWO2006059778A1 (ja) * 2004-12-01 2008-06-05 萬有製薬株式会社 置換ピリドン誘導体
ES2388967T3 (es) 2007-05-04 2012-10-22 Bristol-Myers Squibb Company Agonistas [6,6]- y [6,7]-bicíclicos del receptor GPR119 acoplado a la proteína G
TW200904440A (en) * 2007-07-17 2009-02-01 Bristol Myers Squibb Co Method for modulating GPR119 G protein-coupled receptor and selected compounds
EP2146210A1 (en) 2008-04-07 2010-01-20 Arena Pharmaceuticals, Inc. Methods of using A G protein-coupled receptor to identify peptide YY (PYY) secretagogues and compounds useful in the treatment of conditions modulated by PYY
JP5627574B2 (ja) 2008-06-03 2014-11-19 インターミューン， インコーポレイテッド 炎症性および線維性疾患を治療するための化合物および方法
TW201006821A (en) * 2008-07-16 2010-02-16 Bristol Myers Squibb Co Pyridone and pyridazone analogues as GPR119 modulators
MX2011000664A (es) 2008-07-16 2011-02-24 Schering Corp Derivados biciclicos heterociclicos y uso de los mismos como moduladores de gpr119.
WO2010009208A1 (en) * 2008-07-16 2010-01-21 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
GB0904287D0 (en) 2009-03-12 2009-04-22 Prosidion Ltd Compounds for the treatment of metabolic disorders
WO2010106457A2 (en) * 2009-03-20 2010-09-23 Pfizer Inc. 3-oxa-7-azabicyclo[3.3.1]nonanes
NZ596445A (en) 2009-06-24 2013-04-26 Boehringer Ingelheim Int New compounds, pharmaceutical composition and methods relating thereto
JP2012530758A (ja) 2009-06-24 2012-12-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規化合物、医薬組成物及びそれに関する方法
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2547339A1 (en) 2010-03-18 2013-01-23 Boehringer Ingelheim International GmbH Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
EA201270755A1 (ru) 2010-04-08 2013-03-29 Бристол-Майерс Сквибб Компани Аналоги пиримидинилпиперидинилоксипиридинона в качестве модуляторов рецептора gpr119
WO2011140161A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Benzofuranyl analogues as gpr119 modulators
WO2011140160A1 (en) 2010-05-06 2011-11-10 Bristol-Myers Squibb Company Bicyclic heteroaryl compounds as gpr119 modulators
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
AU2011311183B2 (en) 2010-10-08 2014-09-25 Cadila Healthcare Limited Novel GPR 119 agonists
CA2819889C (en) 2010-12-06 2020-12-15 Confluence Life Sciences, Inc. Substituted pyridinone-pyridinyl compounds
US9359300B2 (en) 2010-12-06 2016-06-07 Confluence Life Sciences, Inc. Methyl/difluorophenyl-methoxy substituted pyridinone-pyridinyl compounds, methyl-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds, and methyl-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
US8822471B2 (en) * 2011-03-14 2014-09-02 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
AU2012267556B9 (en) 2011-06-09 2017-05-11 Rhizen Pharmaceuticals Sa Novel compounds as modulators of GPR-119
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013173198A1 (en) 2012-05-16 2013-11-21 Bristol-Myers Squibb Company Pyrimidinylpiperidinyloxypyridone analogues as gpr119 modulators
HK1210825A1 (en) 2012-07-11 2016-05-06 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
AR092742A1 (es) * 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
EP2921489B1 (en) * 2012-11-13 2017-09-06 Nissan Chemical Industries, Ltd. 2-pyridone compound
CN102993088A (zh) * 2012-12-31 2013-03-27 东华大学 一种4-羟基-2-吡啶酮的制备方法
TW201444821A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代之哌啶化合物及其作為食慾素受體調節劑之用途
TWI621618B (zh) 2013-03-13 2018-04-21 比利時商健生藥品公司 經取代２－氮雜雙環類及其作為食慾素受體調控劑之用途
TW201444849A (zh) 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
CA2917344C (en) 2013-06-07 2021-09-07 Confluence Life Sciences, Inc. Methyl/fluoro-pyridinyl-methoxy substituted pyridinone-pyridinyl compounds and fluoro-pyrimidinyl-methoxy substituted pyridinone-pyridinyl compounds
BR112015031291A2 (pt) 2013-06-20 2017-07-25 Bayer Cropscience Ag derivados de sulfureto de arila e derivados de arilalquil sulfóxido como acaricidas e inseticidas
EP3010889B1 (de) 2013-06-20 2018-10-03 Bayer CropScience Aktiengesellschaft Arylsulfid- und arylsulfoxid-derivate als akarizide und insektizide
EP3019481B1 (de) 2013-07-08 2019-03-06 Bayer CropScience Aktiengesellschaft Sechsgliedrige c-n-verknüpfte arylsulfid- und arylsulfoxid- derivate als schädlingsbekämpfungsmittel
US10233195B2 (en) 2014-04-02 2019-03-19 Intermune, Inc. Anti-fibrotic pyridinones
EP2929883A1 (en) 2014-04-08 2015-10-14 Institut Pasteur Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors
AU2015314851B2 (en) 2014-09-11 2020-01-02 Janssen Pharmaceutica Nv Substituted 2-azabicycles and their use as orexin receptor modulators
WO2016130652A1 (en) 2015-02-10 2016-08-18 Vanderbilt University Negative allosteric modulators of metabotropic glutamate receptor 3
JP6578116B2 (ja) * 2015-03-25 2019-09-18 公益財団法人相模中央化学研究所 一置換（フルオロアルキル）エチレン類及びその製造方法
US10865194B2 (en) 2017-11-03 2020-12-15 Fondazione Istituto Italiano Di Tecnologia Therapeutically active bicyclic-sulphonamides and pharmaceutical compositions
CA3173731A1 (en) 2020-02-28 2021-09-02 Kallyope, Inc. Gpr40 agonists
BR112022019349A2 (pt) 2020-03-27 2022-11-16 Aclaris Therapeutics Inc Forma cristalina, composição farmacêutica, comprimido e método para isolar um composto
CN116323608A (zh) 2020-05-19 2023-06-23 卡尔优普公司 Ampk活化剂
EP4172162A4 (en) 2020-06-26 2024-08-07 Kallyope, Inc. AMPK ACTIVATORS
WO2022081573A1 (en) * 2020-10-12 2022-04-21 University Of Tennessee Research Foundation Transient receptor potential canonical 3 inhibitors and methods of use thereof
CN115504927A (zh) * 2022-08-15 2022-12-23 广西中医药大学 4-甲基-2-对甲苯基-6-羰基吡啶-3-甲酸及其制备方法和用途

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3826643A (en) * 1967-08-07 1974-07-30 American Cyanamid Co Method of controlling undesirable plant species using 3-nitropyridines
US5776983A (en) * 1993-12-21 1998-07-07 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US5488064A (en) * 1994-05-02 1996-01-30 Bristol-Myers Squibb Company Benzo 1,3 dioxole derivatives
US5612359A (en) * 1994-08-26 1997-03-18 Bristol-Myers Squibb Company Substituted biphenyl isoxazole sulfonamides
US5491134A (en) * 1994-09-16 1996-02-13 Bristol-Myers Squibb Company Sulfonic, phosphonic or phosphiniic acid β3 agonist derivatives
US5541204A (en) * 1994-12-02 1996-07-30 Bristol-Myers Squibb Company Aryloxypropanolamine β 3 adrenergic agonists
US5620997A (en) 1995-05-31 1997-04-15 Warner-Lambert Company Isothiazolones
WO1997012613A1 (en) 1995-10-05 1997-04-10 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
US5770615A (en) * 1996-04-04 1998-06-23 Bristol-Myers Squibb Company Catecholamine surrogates useful as β3 agonists
US6566384B1 (en) * 1996-08-07 2003-05-20 Darwin Discovery Ltd. Hydroxamic and carboxylic acid derivatives having MMP and TNF inhibitory activity
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
UA57811C2 (uk) 1997-11-21 2003-07-15 Пфайзер Продактс Інк. Фармацевтична композиція, що містить інгібітор альдозоредуктази та інгібітор глікогенфосфорилази (варіанти), комплект, який її включає, та способи лікування ссавців зі станом інсулінорезистентності
PT1094816E (pt) 1998-07-06 2009-03-10 Bristol Myers Squibb Co Sulfonamidas bifenílicas duplamente antagonistas receptores de angiotensina e endotelina
CA2348740A1 (en) 1998-12-23 2000-07-06 Ruth R. Wexler Thrombin or factor xa inhibitors
AU2001275857A1 (en) 2000-06-29 2002-01-14 Bristol-Myers Squibb Pharma Company Thrombin or factor xa inhibitors
ATE348152T1 (de) 2000-12-01 2007-01-15 Astellas Pharma Inc Verfahren zum screening von diabetes- heilverfahren
AU2002351412B2 (en) * 2001-12-21 2010-05-20 Exelixis Patent Company Llc Modulators of LXR
US7482366B2 (en) 2001-12-21 2009-01-27 X-Ceptor Therapeutics, Inc. Modulators of LXR
ES2334990T3 (es) * 2002-02-14 2010-03-18 Pharmacia Corporation Piridinonas sustituidas como moduladores de p38 map quinasa.
CN102558155A (zh) 2003-01-14 2012-07-11 阿伦纳药品公司 作为代谢调节剂的芳基和杂芳基衍生物及其所涉及的疾病如糖尿病和高血糖症的预防和治疗
WO2004076413A2 (en) 2003-02-24 2004-09-10 Arena Pharmaceuticals, Inc. Phenyl- and pyridylpiperidine-derivatives as modulators of glucose metabolism
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
US7003597B2 (en) * 2003-07-09 2006-02-21 International Business Machines Corporation Dynamic reallocation of data stored in buffers based on packet size
AR045047A1 (es) * 2003-07-11 2005-10-12 Arena Pharm Inc Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
CN100509798C (zh) * 2003-07-11 2009-07-08 艾尼纳制药公司 作为新陈代谢调节剂的三取代芳基和杂芳基衍生物以及预防和治疗与其相关之病症
TWI335328B (en) * 2003-07-14 2011-01-01 Arena Pharm Inc Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related hereto
WO2005025504A2 (en) 2003-09-12 2005-03-24 Kemia, Inc. Modulators of calcitonin and amylin activity
JPWO2005085200A1 (ja) * 2004-03-05 2008-01-17 萬有製薬株式会社 ピリドン誘導体
PL2060266T3 (pl) 2004-03-17 2012-01-31 7Tm Pharma As Selektywni agoniści PP2-36 receptora Y4 do interwencji terapeutycznych
PT1756096E (pt) * 2004-05-03 2009-10-16 Hoffmann La Roche Derivados de indolilo como moduladores do receptor x do fígado
HRP20090093T3 (en) 2004-06-04 2009-03-31 Arena Pharmaceuticals Inc. Substituted aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
EP1838706A1 (en) 2004-12-24 2007-10-03 Prosidion Limited G-protein coupled receptor agonists
MY148521A (en) * 2005-01-10 2013-04-30 Arena Pharm Inc Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
AU2006262425C1 (en) * 2005-06-23 2012-06-21 Emory University Stereoselective synthesis of amino acid analogs for tumor imaging
WO2007003960A1 (en) * 2005-06-30 2007-01-11 Prosidion Limited Gpcr agonists
JP2008545008A (ja) 2005-06-30 2008-12-11 プロシディオン・リミテッド Ｇｐｃｒアゴニスト
ES2388967T3 (es) * 2007-05-04 2012-10-22 Bristol-Myers Squibb Company Agonistas [6,6]- y [6,7]-bicíclicos del receptor GPR119 acoplado a la proteína G
CN101668759A (zh) * 2007-05-04 2010-03-10 百时美施贵宝公司 [6,5]-双环gpr119g蛋白-偶合受体激动剂
TW200904440A (en) * 2007-07-17 2009-02-01 Bristol Myers Squibb Co Method for modulating GPR119 G protein-coupled receptor and selected compounds

Also Published As

Publication number Publication date
PT2170864E (pt) 2011-11-25
US20090023702A1 (en) 2009-01-22
CN101801956A (zh) 2010-08-11
US7928230B2 (en) 2011-04-19
AU2008276055B2 (en) 2013-01-31
PL2173737T3 (pl) 2012-06-29
WO2009012275A9 (en) 2010-03-11
IL228120A0 (en) 2013-09-30
KR20100045471A (ko) 2010-05-03
NZ582661A (en) 2012-03-30
US8178561B2 (en) 2012-05-15
US8513424B2 (en) 2013-08-20
JP2010533726A (ja) 2010-10-28
JP5318867B2 (ja) 2013-10-16
HRP20120221T1 (hr) 2012-04-30
ZA201000151B (en) 2011-03-30
CY1112151T1 (el) 2015-12-09
AU2008276055A1 (en) 2009-01-22
HK1143136A1 (en) 2010-12-24
NZ582664A (en) 2012-03-30
EA201000211A1 (ru) 2010-06-30
CA2693444A1 (en) 2009-01-22
EA201000210A1 (ru) 2010-06-30
CN101801956B (zh) 2013-11-20
AU2008276057B2 (en) 2013-01-31
WO2009012277A1 (en) 2009-01-22
DK2170864T3 (da) 2012-01-16
ZA201000326B (en) 2011-03-30
US8003796B2 (en) 2011-08-23
SI2173737T1 (sl) 2012-05-31
EP2170864B1 (en) 2011-09-14
AR067569A1 (es) 2009-10-14
CN101801957A (zh) 2010-08-11
US20120232048A1 (en) 2012-09-13
PL2170864T3 (pl) 2012-02-29
US20090042919A1 (en) 2009-02-12
AR067568A1 (es) 2009-10-14
CY1112751T1 (el) 2016-02-10
JP5301539B2 (ja) 2013-09-25
CL2008002110A1 (es) 2008-10-24
HK1136298A1 (en) 2010-06-25
TW200904439A (en) 2009-02-01
EP2170864A1 (en) 2010-04-07
CN103550218A (zh) 2014-02-05
DK2173737T3 (da) 2012-05-07
ATE540945T1 (de) 2012-01-15
ES2378914T3 (es) 2012-04-19
CA2693439A1 (en) 2009-01-22
US8232404B2 (en) 2012-07-31
WO2009012275A1 (en) 2009-01-22
SI2170864T1 (sl) 2012-04-30
BRPI0814428A2 (pt) 2015-01-06
CO6160315A2 (es) 2010-05-20
EA018709B1 (ru) 2013-10-30
BRPI0815097A2 (pt) 2018-07-24
PE20090888A1 (es) 2009-07-15
EP2173737A1 (en) 2010-04-14
US20120258959A1 (en) 2012-10-11
JP2010533727A (ja) 2010-10-28
EP2173737B1 (en) 2012-01-11
ATE524460T1 (de) 2011-09-15
PT2173737E (pt) 2012-03-19
TW200904440A (en) 2009-02-01
KR20100051814A (ko) 2010-05-18
PE20090449A1 (es) 2009-04-18
AU2008276057A1 (en) 2009-01-22
HRP20110806T1 (hr) 2011-11-30
US20110190327A1 (en) 2011-08-04
JP2013237680A (ja) 2013-11-28
US20110245227A1 (en) 2011-10-06
CL2008002111A1 (es) 2008-10-24
EA016595B1 (ru) 2012-06-29

Similar Documents

Publication Publication Date Title
AR067568A1 (es) Agonistas de receptor acoplado a proteina g gpr119 de piridona y una composicion farmaceutica que los contiene
AR066437A1 (es) Benzo-oxazinas y pirimidinas condensadas con heterociclos que contienen nitrogeno y oxigeno, composiciones farmaceuticas que las contienen y usos de las mismas para el tratamiento de diabetes,obesidad y enfermedades asociadas a ellas.
AR073254A1 (es) Analogos de piridona y piridazona como moduladores de gpr119
AR066438A1 (es) Compuestos nitrogenados condensados, composiciones farmaceuticas que los contienen y usos de las mismas para el tratamiento de diabetes, obesidad y enfermedades asociadas a ellas.
AR054789A1 (es) Antagonistas del receptor 1 de triazolopiridina canabinoide
AR054814A1 (es) Derivados de piridazina
AR076236A1 (es) Compuestos organicos y sus usos
AR056968A1 (es) Compuestos espiro-oxindol y composiciones farmacéuticas
AR066348A1 (es) Inhibidores de las iap
PE20050676A1 (es) Quinolinas referidas a enfermedades cardiovasculares
PE20190446A1 (es) Moduladores alostericos positivos del receptor muscarinico de acetilcolina m4
AR065266A1 (es) Compuestos y composiciones como inhibidores de la proteasa activadora de canal
CO6251316A2 (es) Inhibidores de enzimas de señales que participan de la proliferacion de las celulas
AR054320A1 (es) Derivados de piridinilo y pirimidinilo sustituidos como moduladores del metabolismo y para tratar trastornos metabolicos. composiciones farmaceuticas
DE602006008474D1 (de) Toren
AR065322A1 (es) 2-aminooxazolinas comoligandos de taar1
ES2396613T3 (es) Imidazopirazinas e imidazotriazinas sustituidas
ES2570756T3 (es) Derivados pirimidinilpirrolopiridinona sustituidos, proceso para su preparación y su uso como inhibidores de cinasa
UY32146A (es) Derivados de las 5-[4-(1,5-dimetil-1h-pirazol-4-il)-1,2,3-triazol-1-il]-6-metil-nicotinamidas n-(sustituidas) y de las n-{5-[4-(1,5-dimetil-1h-pirazol-4-il)-1,2,3-triazol-1-il]-6-metil-piridin-3-il}-benzamidas sustituidas y composiciones conteniéndolos
CO6210724A2 (es) Compuesto heterociclico y composicion farmaceutica del mismo
AR053228A1 (es) Derivados de azol en calidad de inibidores de lipasas y fosfolipasas
ES2587284T3 (es) 5-Fluoro-pirimidinas 2,4-disustituidas como inhibidores selectivos de CDK9
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
DK1664162T3 (da) Polypropylen-blæsefolie
AR107647A1 (es) Derivados de quinazolindion-6-carbonilo y su uso como herbicidas